DSpace Repository

Better Health-Related Quality of Life in Systemic Lupus Erythematosus Predicted by Low Disease Activity State/Remission: Data From the Peruvian Almenara Lupus Cohort

Show simple item record

dc.contributor.author Ugarte Gil, Manuel Francisco
dc.contributor.author Gamboa-Cárdenas, Rocio V.
dc.contributor.author Reátegui-Sokolova, Cristina
dc.contributor.author Medina-Chinchón, Mariela
dc.contributor.author Zevallos, Francisco
dc.contributor.author Elera-Fitzcarrald, Claudia
dc.contributor.author Pimentel Quiroz, Víctor Roman
dc.contributor.author Cucho-Venegas, Jorge M.
dc.contributor.author Rodríguez-Bellido, Zoila
dc.contributor.author Pastor-Asurza, Cesar A.
dc.contributor.author Alarcón, Graciela S.
dc.contributor.author Perich-Campos, Risto
dc.date.accessioned 2020-12-14T16:10:20Z
dc.date.available 2020-12-14T16:10:20Z
dc.date.issued 2019
dc.identifier.uri https://hdl.handle.net/20.500.12866/8835
dc.description.abstract Objective: To determine if low disease activity state (LDAS)/remission predicts a better health‐related quality of life (HRQoL). Methods: Patients with systemic lupus erythematosus from a single center and having completed at least 2 visits were included. Visits were performed every 6 months. HRQoL was measured with the LupusQoL questionnaire. The definition of remission included a Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI‐2K) score of 0, prednisone daily dosage of ≤5 mg/day, and immunosuppressive drugs on maintenance dose. LDAS was defined as a SLEDAI‐2K score of ≤4, prednisone daily dosage of ≤7.5 mg/day, and immunosuppressive drugs as maintenance therapy. For these analyses, remission and LDAS were combined as one variable. Generalized estimating equations were calculated, using as the outcome 1 of each of the 8 components of the LupusQoL questionnaire in the subsequent visit and the activity state in the previous visit. Multivariable models were adjusted for possible confounders. Results: A total of 243 patients were included. During the follow‐up, 590 visits (61.6%) were categorized as LDAS/remission. LDAS/remission predicted a better HRQoL in the components of physical health (B = 4.17 [95% confidence interval (95% CI) 1.20, 7.14]; P = 0.006), pain (B = 6.47 [95% CI 3.18, 9.76]; P < 0.001), planning (B = 4.97 [95% CI 1.43, 8.52]; P = 0.006), burden to others (B = 4.12 [95% CI 0.24, 8.01]; P = 0.037], emotional health (B = 4.50 [95% CI 1.56, 7.44]; P = 0.003), and fatigue (B = 3.25 [95% CI 0.04, 6.47]; P = 0.048). Conclusion: Being in LDAS/remission predicts a better HRQoL, especially in the components of physical health, pain, planning, burden to others, emotional health, and fatigue. en_US
dc.language.iso eng
dc.publisher Wiley
dc.relation.ispartofseries Arthritis Care and Research
dc.rights info:eu-repo/semantics/restrictedAccess
dc.rights.uri https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.subject Systemic lupus erythematosus en_US
dc.subject low disease activity state en_US
dc.subject remission en_US
dc.subject health‐related quality of life en_US
dc.title Better Health-Related Quality of Life in Systemic Lupus Erythematosus Predicted by Low Disease Activity State/Remission: Data From the Peruvian Almenara Lupus Cohort en_US
dc.type info:eu-repo/semantics/article
dc.identifier.doi https://doi.org/10.1002/acr.24009
dc.subject.ocde https://purl.org/pe-repo/ocde/ford#3.02.17
dc.relation.issn 2151-4658


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

info:eu-repo/semantics/restrictedAccess Except where otherwise noted, this item's license is described as info:eu-repo/semantics/restrictedAccess

Search DSpace


Browse

My Account

Statistics